Spero Therapeutics (SPRO) Other Non-Current Assets (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Other Non-Current Assets came in at $153000.0 in Q1 2026, little changed YoY from $153000.0 in Q1 2025, and little changed on a QoQ basis from $153000.0 in Q4 2025.
Spero Therapeutics (SPRO) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Other Non-Current Assets data on file, last reported at $153000.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $153000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $153000.0, changed 0.0% from the prior year.
- Other Non-Current Assets was little changed at $153000.0 in Q1 2026, from $153000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.9 million in Q1 2022 to a low of $153000.0 in Q3 2024.
- A 5-year average of $2.2 million and a median of $434000.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets advanced 13.76% — and 2024, when it tumbled 92.44%.
- Tracing SPRO's Other Non-Current Assets over 5 years: stood at $5.7 million in 2022, then tumbled by 92.42% to $435000.0 in 2023, then sank by 64.83% to $153000.0 in 2024, then changed by 0.0% to $153000.0 in 2025, then changed by 0.0% to $153000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $153000.0 (Q1 2026), $153000.0 (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153,000.00 |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 153,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 153,000.00 |
| Dec 31, 2024 | 153,000.00 |
| Sep 30, 2024 | 153,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 434,000.00 |
| Dec 31, 2023 | 435,000.00 |
| Sep 30, 2023 | 434,000.00 |
| Jun 30, 2023 | 5.74 Mn |
| Mar 31, 2023 | 5.74 Mn |
| Dec 31, 2022 | 5.74 Mn |
| Sep 30, 2022 | 5.74 Mn |
| Jun 30, 2022 | 5.47 Mn |
| Mar 31, 2022 | 5.93 Mn |
| Dec 31, 2021 | 5.64 Mn |
| Sep 30, 2021 | 5.21 Mn |